NasdaqGM:VCYT
NasdaqGM:VCYTBiotechs

Why Veracyte (VCYT) Is Up 18.0% After Raising 2025 Outlook and Highlighting Afirma Progress

Veracyte reported strong third quarter 2025 results, raising full-year revenue guidance to US$506–510 million and highlighting gains in Decipher and Afirma testing as well as positive net income growth. Recent research publications suggest Veracyte’s Afirma GRID platform could transform pre-surgical thyroid cancer risk assessment, showcasing ongoing clinical innovation and depth of its genomic data capabilities. With the upgraded revenue outlook underscoring operational momentum, we'll...
NasdaqGS:SYNA
NasdaqGS:SYNASemiconductor

Does Recent Semiconductor Optimism Present an Opportunity in Synaptics Stock for 2025?

Curious whether Synaptics stock is undervalued, overhyped, or hiding an opportunity most investors are missing? You are not alone; plenty of people are wondering the same thing. The stock has had a choppy ride lately, slipping 2.6% in the last week but gaining 4.5% over the past month, and is still down 16.8% year-to-date. These swings hint at shifting perceptions around growth and risk. Recent news in the semiconductor space, such as industry consolidation and fresh optimism about...
NasdaqGM:ASST
NasdaqGM:ASSTCapital Markets

Why Strive Asset Management (ASST) Is Up 19.8% After Launching High-Yield Preferred Stock to Fund Bitcoin Expansion

Strive Asset Management recently announced the issuance of 1.25 million shares of a new preferred stock, SATA, offering an initial 12% annual dividend to raise funds for increased Bitcoin purchases and operational expansion. This move highlights the company's intent to finance digital asset growth without diluting current shareholders, drawing inspiration from approaches used by other bitcoin-focused firms. We’ll explore how Strive’s plan to use preferred stock offerings for bitcoin...